ACTUATE THERAPEUTICS, INC.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $10.3M | $18.7M | $21.7M | — |
| Operating expenses | $22.5M | $25.2M | $25.0M | — |
| Operating income | -$22.5M | -$25.2M | -$25.0M | — |
| Interest expense | $20,250 | $18,717 | $43,641 | — |
| Income tax expense | $800 | $800 | $0 | — |
| Net income | -$22.2M | -$27.3M | -$24.7M | — |
| Balance Sheet | ||||
| Cash and equivalents | $13.2M | $8.6M | — | — |
| Current assets | $13.6M | $9.2M | $3.0M | — |
| Total assets | $14.0M | $9.3M | $3.0M | — |
| Current liabilities | $5.7M | $8.8M | $6.9M | — |
| Total liabilities | $6.1M | $9.2M | $8.4M | — |
| Stockholders' equity | $7.9M | $104,186 | -$99.6M | -$75.3M |
| Cash Flow Statement | ||||
| Cash from operations | -$19.2M | -$21.8M | -$21.6M | — |
| Stock-based compensation | $6.0M | $2.0M | $423,539 | — |
Shares outstanding 23.9M · Free float 37.7%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.